Erste Asset Management GmbH Buys New Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Erste Asset Management GmbH purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 260,000 shares of the company’s stock, valued at approximately $10,136,000. Erste Asset Management GmbH owned about 0.54% of Mirum Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of MIRM. Raymond James & Associates lifted its holdings in shares of Mirum Pharmaceuticals by 10.5% in the 2nd quarter. Raymond James & Associates now owns 144,214 shares of the company’s stock valued at $4,931,000 after purchasing an additional 13,651 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 64.9% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 104,770 shares of the company’s stock valued at $3,582,000 after acquiring an additional 41,236 shares during the period. Secure Asset Management LLC grew its position in shares of Mirum Pharmaceuticals by 8.6% during the second quarter. Secure Asset Management LLC now owns 45,904 shares of the company’s stock worth $1,569,000 after acquiring an additional 3,630 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Mirum Pharmaceuticals by 48.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock valued at $4,889,000 after acquiring an additional 46,506 shares during the period. Finally, Commonwealth Equity Services LLC raised its position in Mirum Pharmaceuticals by 17.1% in the 2nd quarter. Commonwealth Equity Services LLC now owns 14,050 shares of the company’s stock valued at $480,000 after purchasing an additional 2,050 shares during the last quarter.

Mirum Pharmaceuticals Trading Down 0.9 %

Shares of Mirum Pharmaceuticals stock opened at $46.22 on Monday. The company has a 50-day moving average of $40.93 and a two-hundred day moving average of $37.49. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $48.89. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.22 billion, a PE ratio of -22.88 and a beta of 1.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period in the prior year, the business earned ($0.57) earnings per share. The company’s quarterly revenue was up 89.4% on a year-over-year basis. On average, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Insider Activity

In other news, SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the transaction, the senior vice president now directly owns 2,426 shares of the company’s stock, valued at $114,264.60. The trade was a 50.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 22.87% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on MIRM shares. Cantor Fitzgerald lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Leerink Partners upped their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Evercore ISI lifted their price objective on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $57.73.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.